Abcam, a producer, distributor and seller of protein research tools, agreed to acquire Marker Gene Technologies, which develops innovative new products for the biotechnology and medical industries. Financial terms were not disclosed. "Following the recent acquisition of Expedeon's proteomics and immunology business, and aligned with our broader antibody-conjugation strategy, the acquisition of MGT brings additional proprietary assay development technologies and labelling capabilities to Abcam. MGT's team have expertise in the areas of biology, organic synthesis and fluorescence chemistry and are experienced in the creation of detection tools that enable enhanced understanding of biological processes," Abcam.